Flow cytometric minimal residual disease monitoring in children with acute lymphoblastic leukemia treated by regimens with reduced intensity

A. M. Popov; Попов А. М.; Y. Yu. Verzhbitskaya; Вержбицкая Т. Ю.; G. A. Tsaur; Цаур Г. А.; A. G. Solodovnikov; Солодовников А. Г.; O. R. Arakaev; Аракаев О. Р.; O. V. Streneva; Стренева О. В.; O. P Khlebnikova; Хлебникова О. П.; E. V. Shorikov; Шориков Е. В.; L. I. Saveliev; Савельев Л. И.; S. N. Lagoyko; Лагойко С. Н.; Yu. V. Rumyantseva; Румянцева Ю. В.; A. I. Karachunskiy; Карачунский А. И.; L. G. Fechina; Фечина Л. Г.

doi:10.17650/1818-8346-2015-10-4-44-55

Flow cytometric minimal residual disease monitoring in children with acute lymphoblastic leukemia treated by regimens with reduced intensity

Authors: Popov A.M.¹, Verzhbitskaya Y.Y.²^,3, Tsaur G.A.²^,3^,4, Solodovnikov A.G.³, Arakaev O.R.², Streneva O.V.²^,3, Khlebnikova O.P², Shorikov E.V.²^,3, Saveliev L.I.²^,4, Lagoyko S.N.¹, Rumyantseva Y.V.¹^,5, Karachunskiy A.I.¹^,5, Fechina L.G.²^,3
Affiliations:
1. Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia
2. Regional Children Clinical Hospital
3. Institute of Medical Cell Technologies
4. Ural State Medical University, Ministry of Health of Russia
5. N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Issue: Vol 10, No 4 (2015)
Pages: 44-55
Section: BASIC RESEARCH
Published: 23.12.2015
URL: https://oncohematology.abvpress.ru/ongm/article/view/167
DOI: https://doi.org/10.17650/1818-8346-2015-10-4-44-55
ID: 167

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

191 consecutive unselected children with acute lymphoblastic leukemia aged from 1 to 16 years were enrolled in the study. Bone marrow samples were obtained at the time of initial diagnostics as well as at days 15 (n = 188), 36 (n = 191), and 85 (n = 187) of remission induction. Minimal residual disease (MRD) was assessed by 6–10-color flow cytometry. Flow cytometry data at day 15 allowed distinguishing three patients groups with significantly different outcome (p ˂ 0.0001): 35.64 % patients with MRD < 0.1 % represented 5-year event-free survival (EFS) of 100 %; 48.40 % cases with 0.1 % ≤ MRD< 10 % had EFS 84.6 ± 4.2 %; 15.96 % patients with very high MRD (≥ 10 %) belonged to group with poor outcome (EFS 56.7 ± 9.0 %). At the end of remission induction (day 36) 36 children (18.85 %) with MRD higher than 0.1 % had significantly worse outcome compared to remaining ones (EFS 49.4 ± 9.0 and 93.5 ± 2.1 % respectively; p ˂ 0.0001). From a clinical standpoint it is relevant to evaluate both low-risk and high-risk criteria. Multivariate analysis showed that day 15 MRD data is better for low-risk patients definition while end-induction MRD is the strongest unfavorable prognostic factor.

Keywords

acute lymphoblastic leukemia, minimal residual disease, flow cytometry

About the authors

A. M. Popov

Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia

Author for correspondence.
Email: uralcytometry@gmail.com
1 Samory Mashela St., Moscow, 117997 Russian Federation

Y. Yu. Verzhbitskaya

Regional Children Clinical Hospital;
Institute of Medical Cell Technologies

32 S. Deryabinoy St., Ekaterinburg, 620149;

22a Karla Marksa St., Ekaterinburg, 620026

Russian Federation

G. A. Tsaur

Regional Children Clinical Hospital;
Institute of Medical Cell Technologies;
Ural State Medical University, Ministry of Health of Russia

32 S. Deryabinoy St., Ekaterinburg, 620149;

22a Karla Marksa St., Ekaterinburg, 620026;

3 Repina St., Ekaterinburg, 620028

Russian Federation

A. G. Solodovnikov

Institute of Medical Cell Technologies

22a Karla Marksa St., Ekaterinburg, 620026 Russian Federation

O. R. Arakaev

Regional Children Clinical Hospital

32 S. Deryabinoy St., Ekaterinburg, 620149 Russian Federation

O. V. Streneva

Regional Children Clinical Hospital;
Institute of Medical Cell Technologies

32 S. Deryabinoy St., Ekaterinburg, 620149;

22a Karla Marksa St., Ekaterinburg, 620026

Russian Federation

O. P Khlebnikova

Regional Children Clinical Hospital

32 S. Deryabinoy St., Ekaterinburg, 620149 Russian Federation

E. V. Shorikov

Regional Children Clinical Hospital;
Institute of Medical Cell Technologies

32 S. Deryabinoy St., Ekaterinburg, 620149;

22a Karla Marksa St., Ekaterinburg, 620026

Russian Federation

L. I. Saveliev

Regional Children Clinical Hospital;
Ural State Medical University, Ministry of Health of Russia

32 S. Deryabinoy St., Ekaterinburg, 620149;

3 Repina St., Ekaterinburg, 620028

Russian Federation

S. N. Lagoyko

Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia

1 Samory Mashela St., Moscow, 117997 Russian Federation

Yu. V. Rumyantseva

Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia;
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

1 Samory Mashela St., Moscow, 117997;

1 Ostrovityanova St., Moscow, 117997

Russian Federation

A. I. Karachunskiy

1 Samory Mashela St., Moscow, 117997;

1 Ostrovityanova St., Moscow, 117997

Russian Federation

L. G. Fechina

Regional Children Clinical Hospital;
Institute of Medical Cell Technologies

32 S. Deryabinoy St., Ekaterinburg, 620149;

22a Karla Marksa St., Ekaterinburg, 620026

Russian Federation

References

Supplementary files

Supplementary Files

Action

1. JATS XML

Download

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register